GoodRx (GDRX) announced the availability of Repatha, a cholesterol-lowering therapy, at a significantly reduced cash price. Patients can use GoodRx to access Repatha for $239 at more than 70,000 pharmacies nationwide, a savings of nearly 60% off the retail pharmacy list price.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- Unusually active option classes on open October 2nd
- Hold Rating on GoodRx Holdings Amid Uncertainties and Potential Partnerships
- GoodRx possibly partnering with TrumpRx ‘welcome news,’ says Citi
- GoodRx jumps 21% to $5.14 in late trading
- GoodRx Holdings: Strategic Advancements and Industry Confidence Justify Buy Rating